Physician profile
Peter Kim
NPI 1417925900
$3,730.88
in general payments reported to CMS, 2019-2025
34 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $737 · 2021: $714 · 2022: $323 · 2023: $589 · 2024: $376 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,386.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $509.60 | 2019-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals Lp | $335.90 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $309.51 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Gilead Sciences, INC. | $296.24 | 2021-2025 | |
| Novo Nordisk INC | $288.10 | 2019-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $254.72 | 2019-2023 | Myrbetriq |
| Amarin Pharma, INC. | $198.23 | 2019-2022 | |
| Abbvie INC. | $185.54 | 2021-2024 | |
| Lilly USA, LLC | $149.40 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Scilex Pharmaceuticals INC. | $106.29 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $104.83 | 2019-2021 | |
| Allergan, INC. | $103.90 | 2019-2020 | |
| Exact Sciences Corporation | $99.82 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $98.85 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $78.33 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $70.27 | 2021 | |
| Sumitomo Pharma America, INC. | $69.50 | 2023 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $68.17 | 2021-2022 | |
| Horizon Therapeutics Plc | $64.65 | 2022-2023 | Krystexxa |
| Kowa Pharmaceuticals America, INC. | $46.47 | 2019-2021 | |
| Abbott Laboratories | $40.48 | 2022-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $38.91 | 2019-2021 | |
| Sanofi Pasteur INC. | $28.90 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.23 | 2019 | |
| Genentech USA, INC. | $21.17 | 2020 | |
| Ibsa Pharma INC. | $18.37 | 2023 | Tirosint, Licart |
| Biogen, INC. | $18.24 | 2021 | |
| Adamas Pharmaceuticals, INC. | $16.54 | 2020 | |
| Phadia US INC. | $15.85 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.36 | 2025 | Rexulti |
| Esperion Therapeutics, INC. | $15.07 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.28 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.25 | 2021 | |
| Seqirus USA INC | $13.91 | 2025 | Flucelvax, Fluad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.